Workflow
VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies
VACHVoyager Acquisition Corp.(VACH) Newsfilter·2025-04-23 05:00

Company Overview - VERAXA Biotech AG is an emerging leader in designing novel cancer therapies, focusing on a comprehensive pipeline of next-generation cancer therapies through its proprietary Bi-Targeted Antibody Cytotoxicity (BiTAC) technology platform [1][2] - The company is advancing a premier drug discovery and development engine for antibody-drug conjugates (ADCs) and other novel antibody-based therapy concepts [2] Business Combination - VERAXA has entered into a definitive business combination agreement with Voyager Acquisition Corp, which will create a publicly traded clinical-stage biopharmaceutical company [1] - The transaction values VERAXA at a pre-money equity value of 1.3billion,withexistingshareholdersreceivingapproximately130millionordinarysharesofthecombinedcompany[6][10]−Thebusinesscombinationisexpectedtocloseinthefourthquarterof2025,subjecttoshareholderapprovalandcustomaryclosingconditions[13]MarketPotential−TheglobalTCEmarketisprojectedtoreach1.3 billion, with existing shareholders receiving approximately 130 million ordinary shares of the combined company [6][10] - The business combination is expected to close in the fourth quarter of 2025, subject to shareholder approval and customary closing conditions [13] Market Potential - The global TCE market is projected to reach 112 billion by 2030, with a compound annual growth rate (CAGR) of over 44%, while the global ADC market is expected to reach 57billionby2030,withaCAGRcloseto3057 billion by 2030, with a CAGR close to 30% [3] - The company aims to address the limitations of current cancer therapies by developing next-generation therapies with improved safety and efficacy profiles [4] Pipeline and Development - VERAXA's pipeline includes nine discovery and development programs at various stages, with the most advanced asset, VX-A901, showing potent anti-cancer activity [4] - The company is pursuing both internal innovation and strategic partnerships to enhance its pipeline, anticipating three proprietary development programs in the clinic by 2029 [4][6] Leadership and Support - The leadership team includes experienced professionals such as CEO Christoph Antz, Ph.D., and CBO Heinz Schwer, Ph.D., MBA, both of whom have backgrounds in venture capital [5] - The company is supported by international scientific advisors, including experts in immuno-oncology [8] Financial Strategy - VERAXA is actively raising a crossover financing round expected to close before the business combination, which will provide sufficient capital for the next two years [12] - Upon closing, the combined entity is expected to have an implied pro forma equity value of approximately 1.64 billion, with access to up to $253 million in cash held in trust by Voyager [11]